FDA says Herbal Vitality's herbal tinctures were unapproved drugs and misbranded supplements.
What happened
FDA inspected Herbal Vitality's manufacturing facility in Sedona, Arizona, from July 11 through July 15, 2022, and reviewed finished product labels and the product catalog. FDA found the labels and catalog claimed many products would cure, treat, or prevent diseases such as kidney stones, cold and flu, Lyme disease, COPD, and other conditions, making them unapproved new drugs. FDA also found dietary supplement current good manufacturing practice (CGMP) violations, including missing contamination limits, missing finished-product specifications, releases without quality control review, and misbranded supplement labeling.
What FDA found
FDA says many products were unapproved new drugs because their names and catalog claims said they cure, treat, or prevent diseases such as kidney stones, cold/flu, Lyme, and COPD.
FD&C Act §§ 201(g)(1)(B), 201(p), 301(d), 505(a) [21 U.S.C. §§ 321(g)(1)(B), 321(p), 331(d), 355(a)]FDA says several products were misbranded drugs because they were for diseases a layperson cannot safely self-diagnose or treat, so adequate directions could not be written.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]; § 301(a) [21 U.S.C. § 331(a)]FDA says the company did not set limits for microbes, pesticides, and heavy metals in components used in products such as Immune Tonic and Children’s Tonsillitis/Otitis.
21 CFR 111.70(b)(3)FDA says the company did not set finished-product specifications for identity, purity, strength, composition, or contamination for any multi-ingredient supplement.
21 CFR 111.70(e)FDA says batches were released for distribution without quality control review and approval.
21 CFR 111.123(a)(8)FDA says supplement labels were misbranded, with missing ingredient names, wrong serving sizes, or incomplete Supplement Facts.
FD&C Act § 403(i)(2), 403(q)(1)(A), 403(q)(5)(F) [21 U.S.C. § 343]; 21 CFR 101.4(h), 101.36
What FDA wants
FDA tells the company to correct the violations, including stopping disease claims and fixing manufacturing quality and labeling problems. The provided letter does not state a response deadline.
Who should pay attention
- brands that buy herbal tinctures from contract manufacturers
- retailers and distributors selling herbal supplements with disease claims
- consumers, especially parents and pregnant people using these products
This is a summary. Read the original letter on fda.gov.